💊 Oral Peptide Delivery Systems
Oral peptide drugs were once the industry's "Holy Grail" challenge. The successful commercialization of SNAC delivery technology (oral semaglutide Rybelsus®) has proven the clinical and commercial viability of oral peptides, sparking a global R&D boom.
1. Core Challenges of Oral Peptide Delivery
The oral bioavailability of peptides is extremely low, with major barriers including:
| Barrier Factor |
Severity |
Mechanism Description |
| Gastric Acid Denaturation |
🔴 Severe |
Stomach pH 1.5–3.5 denatures and inactivates peptide structure |
| Enzymatic Degradation |
🔴 Severe |
Pepsin, trypsin, chymotrypsin rapidly hydrolyze peptide bonds |
| Mucosal Barrier |
🟡 Moderate |
Tight junctions between intestinal epithelial cells restrict macromolecule passage (>500 Da) |
| First-Pass Effect |
🟡 Moderate |
Hepatic first-pass metabolism further reduces systemic availability by 50–90% |
| Mucus Layer Obstruction |
🟡 Moderate |
Intestinal mucus layer traps and clears peptide molecules |
Outcome
The oral bioavailability of naked peptides (without delivery technology) is typically <0.1%. Even with enhancers, it generally falls in the 0.5–2% range. However, commercially, 1% bioavailability is already sufficient to produce therapeutic efficacy for highly potent GLP-1 class drugs.
2. Major Oral Delivery Technologies
2.1 Permeation Enhancers
| Technology Type |
Representative Molecule |
Mechanism of Action |
Clinical Application |
| SNAC (Sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) |
Novo Nordisk |
Hydrophobic ion pairing + reduced gastric enzyme degradation + increased transcellular transport |
✔ Oral semaglutide (Rybelsus®, launched 2020) |
| Sodium Caprate / Caprate Esters |
Oramed (POD™ Technology) |
Transient tight junction opening + protease inhibition |
✔ Oral insulin (ORMD-0801, Phase III) |
| C8/C10 Medium-Chain Fatty Acid Salts |
Choline caprate |
Membrane fluidity modulation + tight junction regulation |
✔ Oral GLP-1 (multiple clinical trials) |
| CapMate™ |
Chiasma |
Permeation enhancer + pH modulation |
✔ Oral octreotide (Mycapssa®, launched 2020) |
SNAC Delivery Mechanism Detailed:
Oral → SNAC forms hydrophobic ion pairs in stomach + local pH elevation → protects peptide
→ Trans-gastric epithelial transport (increased lipophilicity) → enters systemic circulation
→ Avoids intestinal enzymatic degradation → bioavailability ~0.5–1%
2.2 Enzyme Inhibitors
| Inhibitor |
Targeted Enzymes |
Applicable Peptides |
Development Stage |
| Aprotinin |
Broad-spectrum protease inhibition |
Insulin, GLP-1 |
Clinical research |
| Camostat mesylate |
Serine proteases |
Multiple |
Approved drug (pancreatic enzyme inhibitor) |
| Soybean trypsin inhibitor (SBTI) |
Trypsin |
Multiple |
Food / supplement grade |
2.3 Nanoparticle Carriers
| Carrier Type |
Material |
Drug Loading Mechanism |
Advantages |
Representative Company/Project |
| Lipid Nanoparticles (LNP) |
Phospholipid + Cholesterol |
Encapsulation in lipid bilayer |
Protection + sustained release |
Acuitas |
| Polymer Nanoparticles |
PLGA / PEG-PLGA |
Encapsulation in polymer matrix |
Controlled release + long circulation |
Novo Nordisk |
| Chitosan Nanoparticles |
Chitosan |
Positive charge adhesion + encapsulation |
Good mucoadhesion |
Academic / CMC |
| Micelle Carriers |
Amphiphilic block copolymers |
Hydrophobic core drug loading |
Small size (<100 nm) |
Multiple Biotechs |
2.4 Enteric Coating
Enteric coatings protect peptides from gastric acid/pepsin degradation, releasing them at specific intestinal pH:
| Coating Material |
Release pH |
Suitable Delivery Site |
Commercial Case |
| Eudragit L100 |
≥6.0 |
Duodenum / Jejunum |
Mycapssa® |
| Eudragit S100 |
≥7.0 |
Ileum / Colon |
Clinical studies |
| HPMC-AS |
≥5.5 |
Duodenum |
Multiple |
3. Key Companies & Products
| Company |
Core Platform |
Lead Pipeline |
Highest Phase |
Assessment |
| Novo Nordisk |
SNAC delivery |
Oral semaglutide (Rybelsus®) |
✅ Marketed (2019 FDA) |
Industry benchmark |
| Oramed Pharma |
POD™ (caprate + enzyme inhibition) |
Oral insulin ORMD-0801 |
Phase III completed (2023) |
Controversial, requires additional trials |
| Chiasma |
TPE (caprate derivative + pH) |
Oral octreotide Mycapssa® |
✅ Marketed (2020 FDA) |
Acromegaly |
| Entera Bio |
NAC (N-acetylcysteine) |
Oral PTH (1-34) |
Phase II |
Osteoporosis |
| Allergan/Aptalis |
MMX™ release system |
Oral colonic delivery |
Clinical application |
Combination formulations |
4. Clinical Data Comparison: Oral Peptide Bioavailability
| Drug/Candidate |
Delivery Technology |
Oral Bioavailability |
Equivalent Injection Dose Ratio |
Clinical Status |
| Rybelsus® (oral semaglutide 14 mg) |
SNAC |
~0.8–1.0% |
1:50 (14 mg vs 0.5 mg injection) |
✅ Marketed |
| Mycapssa® (oral octreotide 20 mg) |
TPE |
~0.5% |
1:20 |
✅ Marketed |
| ORMD-0801 (oral insulin) |
POD™ |
~0.5–1.5% |
1:30 |
Phase III completed |
| OG2023 (oral GLP-1) |
Liposome |
~1.2% |
1:40 |
Phase I |
| Novel oral PTH(1-34) |
NAC |
~1.5–2.0% |
1:25 |
Phase II |
| Oral calcitonin |
Chitosan nanoparticles |
~1.0% |
1:20 |
Phase II |
Key Takeaways
- Current oral peptide bioavailability is generally in the 0.5–2% range, but this is already sufficient for clinical efficacy
- SNAC technology is the only platform that has entered large-scale commercialization, with Rybelsus® achieving 2024 global sales of $2.86B
- Next-generation target: using combination delivery strategies (enhancer + enzyme inhibition + coating) to increase bioavailability to 3–5%
5. Industry Trends & Outlook
| Trend |
Description |
Expected Timeline |
| Next-Generation Enhancer Development |
Novel molecules derived from SNAC structure with improved delivery efficiency |
2025–2028 |
| Long-Acting Oral Peptides |
Oral + fatty acid chain modification for once-weekly oral formulations |
2026–2029 |
| Oral GLP-1/GIP Dual Receptor |
Race to develop oral formulations of tirzepatide-like analogs |
2025–2027 |
| Oral PDC Anticancer Drugs |
Exploratory research on oral peptide-drug conjugates |
2027+ |
| AI-Assisted Carrier Design |
ML-based optimization of lipid/polymer carrier combinations |
2025–2027 |
6. Oral Peptide Delivery System Comparison Snapshot
| Technology Platform |
Complexity |
Formulation Cost |
Peptide Suitability |
Clinical Validation |
Commercial Scale |
| SNAC Class |
Medium |
Medium |
GLP-1 class |
✅ Strongest |
🏭🏭🏭🏭🏭 |
| Caprate/Caprylate Salts |
Low |
Low |
Multiple |
✅ Good |
🏭🏭🏭 |
| Lipid Nanoparticles |
High |
Mid–High |
Hydrophilic/Amphiphilic |
⚠️ Limited |
🏭🏭 |
| Polymer Nanoparticles |
High |
High |
Broad |
⚠️ Limited |
🏭 |
| Enteric/Controlled Release Coating |
Medium |
Mid–Low |
Broad |
✅ Applied |
🏭🏭🏭🏭 |
| Combination Strategy (above mixed) |
High |
Mid–High |
Broadcast |
🔬 R&D |
— |
💡 Oral Peptide CDMO Services: SENO Biotechnology has end-to-end capabilities in oral peptide formulation development, from preformulation research and dosage form development to pilot-scale production, and has supported multiple GLP-1 oral generic projects with SNAC-related formulation development. Visit our platform for GMP-grade peptide production and oral formulation services → senopeptide.com/platforms/